Braveheart Biotech Seeks IPO for Heart Drug

Braveheart Bio is moving forward with plans for a public stock offering. The biotech company wants to list its shares on the Nasdaq stock exchange. This step will help fund its important work on a new heart drug.

The company's drug treats serious heart problems. It is now in phase 3 trials. This is the last stage of testing before the drug can get approval. Braveheart Bio licensed the drug from Hengrui Pharma.

The money raised from the IPO will help finish these trials. It will also prepare the drug for wider use. This move shows Braveheart Bio's commitment to bringing new treatments to patients with heart disease.

Source: FierceBiotech